JP2010519211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519211A5 JP2010519211A5 JP2009549723A JP2009549723A JP2010519211A5 JP 2010519211 A5 JP2010519211 A5 JP 2010519211A5 JP 2009549723 A JP2009549723 A JP 2009549723A JP 2009549723 A JP2009549723 A JP 2009549723A JP 2010519211 A5 JP2010519211 A5 JP 2010519211A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bladder
- botulinum toxin
- surface area
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 210000003932 Urinary Bladder Anatomy 0.000 claims 16
- 108010043024 Botulinum Toxins Proteins 0.000 claims 12
- 229940053031 botulinum toxin Drugs 0.000 claims 12
- 108090000790 Enzymes Proteins 0.000 claims 9
- 102000004190 Enzymes Human genes 0.000 claims 9
- 210000002744 Extracellular Matrix Anatomy 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 claims 6
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 claims 6
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 claims 6
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 6
- 229940020899 hematological Enzymes Drugs 0.000 claims 6
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 claims 6
- 230000001079 digestive Effects 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 229940088598 Enzyme Drugs 0.000 claims 3
- 210000003491 Skin Anatomy 0.000 claims 3
- 229960001231 Choline Drugs 0.000 claims 2
- 102000020504 Collagenase family Human genes 0.000 claims 2
- 108060005980 Collagenase family Proteins 0.000 claims 2
- 102000001974 Hyaluronidase Human genes 0.000 claims 2
- 108010074224 Hyaluronoglucosaminidase Proteins 0.000 claims 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims 2
- 210000002307 Prostate Anatomy 0.000 claims 2
- 102000003978 Tissue plasminogen activator Human genes 0.000 claims 2
- 108090000373 Tissue plasminogen activator Proteins 0.000 claims 2
- 201000008848 bladder disease Diseases 0.000 claims 2
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 claims 2
- 230000001713 cholinergic Effects 0.000 claims 2
- 229960002424 collagenase Drugs 0.000 claims 2
- 229960002773 hyaluronidase Drugs 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 230000037315 hyperhidrosis Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
Claims (15)
- コリン作用の影響を受ける障害を有する患者を処置するためのボツリヌス毒素含有組成物であって、
a)細胞外マトリックス消化酵素を含有する第1組成物を患者の表面領域に投与するステップ、
b)細胞外マトリックス消化酵素が表面領域を通して拡散してターゲットに達するように、十分な時間を経過させるステップ、
d)ボツリヌス毒素含有組成物を表面領域に投与するステップ;および
e)ボツリヌス毒素が表面領域を通して拡散してターゲットに達するのに十分な時間をとるステップ
を含み、それによって、コリン作用の影響を受ける障害に関連する少なくとも1つの症状を軽減し、コリン作用の影響を受ける障害を有する患者を処置する方法において用いられる組成物。 - 表面領域が管腔表面領域である、請求項1に記載の組成物。
- 管腔表面領域が膀胱管腔表面領域である、請求項2に記載の組成物。
- ターゲットが排尿筋を含み、
(i) 膀胱管腔表面領域への細胞外マトリックス消化酵素およびボツリヌス毒素の投与を、膀胱内への細胞外マトリックス消化酵素およびボツリヌス毒素の点滴注入によって行うか、または
(ii) 細胞外マトリックス消化酵素の投与を、膀胱の膀胱壁への第1組成物の注射によって行い、ボツリヌス毒素含有組成物の投与を膀胱内への点滴注入によって行うか、または
(iii)細胞外マトリックス消化酵素の投与を膀胱内への第1組成物の点滴注入によって行い、ボツリヌス毒素の投与を膀胱の膀胱壁へのボツリヌス毒素含有組成物の注射によって行う、請求項3に記載の組成物。 - ボツリヌス毒素含有組成物の投与を、膀胱壁への20未満の注射数、または膀胱壁への10未満の注射数、または膀胱壁への1〜5の注射数で行う、請求項4に記載の組成物。
- ボツリヌス毒素がA、B、C1、D、E、FおよびG型ボツリヌス毒素からなる群より選択される、請求項4に記載の組成物。
- 方法が、ステップ(a)の前に膀胱を空にするステップ、ステップ(b)の後に膀胱を空にするステップ、およびステップ(e)の後に膀胱を空にするステップをさらに含む、請求項4に記載の組成物。
- コリン作用の影響を受ける障害が、膀胱障害および前立腺障害からなる群より選択される泌尿器障害である、請求項2に記載の組成物。
- 膀胱障害が、過活動膀胱、肥大膀胱頚部および排尿筋反射亢進からなる群より選択される、請求項8に記載の組成物。
- 前立腺障害が、良性前立腺肥大、前立腺炎および前立腺がんからなる群より選択される、請求項8に記載の組成物。
- 方法が、場合によってはステップ(b)の後に第1組成物を除去するステップ、および場合によってはステップ(e)の後にボツリヌス毒素含有組成物を除去するステップをさらに含む、請求項1に記載の組成物。
- コリン作用の影響を受ける障害が多汗症であり、患者の表面領域が、腋窩皮膚表面領域、手掌皮膚表面領域および足底皮膚表面領域からなる群より選択される、請求項11に記載の組成物。
- 細胞外マトリックス消化酵素が、ヒアルロニダーゼ、組織プラスミノゲン活性化因子またはコラゲナーゼである、請求項1に記載の組成物。
- 細胞外マトリックス消化酵素を含有する第1組成物、およびボツリヌス毒素を含有する第2組成物からなるキット。
- 細胞外マトリックス消化酵素が、ヒアルロニダーゼ、組織プラスミノゲン活性化因子またはコラゲナーゼである、請求項14に記載のキット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89005207P | 2007-02-15 | 2007-02-15 | |
PCT/US2008/053989 WO2008101098A2 (en) | 2007-02-15 | 2008-02-14 | Use of botulinum toxin and enzymes for treating bladder or prostata disorders, or hyperhydrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010519211A JP2010519211A (ja) | 2010-06-03 |
JP2010519211A5 true JP2010519211A5 (ja) | 2011-03-31 |
Family
ID=39689504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009549723A Pending JP2010519211A (ja) | 2007-02-15 | 2008-02-14 | 膀胱もしくは前立腺障害または多汗症を処置するためのボツリヌス毒素および酵素の使用 |
Country Status (7)
Country | Link |
---|---|
US (4) | US8388952B2 (ja) |
EP (2) | EP2583687B1 (ja) |
JP (1) | JP2010519211A (ja) |
CA (1) | CA2678038C (ja) |
ES (2) | ES2441961T3 (ja) |
HK (1) | HK1184055A1 (ja) |
WO (1) | WO2008101098A2 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096164A1 (en) | 2005-03-03 | 2006-09-14 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
EP2583687B1 (en) * | 2007-02-15 | 2014-08-27 | Allergan, Inc. | Use of botulinum toxin for treating hyperhydrosis |
US8273721B2 (en) * | 2008-03-05 | 2012-09-25 | Endo Pharmaceuticals Solutions Inc. | Combination treatment for bladder cancer |
ES2724588T3 (es) | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
RS56460B1 (sr) * | 2011-01-07 | 2018-01-31 | Revance Therapeutics Inc | Topikalna supstanca koja sadrži botulinski toksin i boju |
JP2014510045A (ja) * | 2011-02-08 | 2014-04-24 | ハロザイム インコーポレイテッド | ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用 |
US9764009B2 (en) * | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
EP2731590B1 (en) * | 2011-07-13 | 2018-05-23 | The Foundry, LLC | Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets |
JP6092205B2 (ja) | 2011-07-14 | 2017-03-08 | アラーガン、インコーポレイテッドAllergan,Incorporated | 性的行為に関連した失禁の治療方法 |
US10307467B2 (en) | 2014-07-16 | 2019-06-04 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
WO2016102068A1 (en) | 2014-12-23 | 2016-06-30 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
CN107206175B (zh) | 2015-02-03 | 2021-06-01 | 莫茨制药有限及两合公司 | 肉毒杆菌毒素预填充式容器 |
RU2605624C1 (ru) * | 2015-11-23 | 2016-12-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Способ лечения детрузорной гиперактивности |
US20210162026A1 (en) | 2017-08-28 | 2021-06-03 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69019141T2 (de) | 1989-01-27 | 1996-01-18 | Immunolytics Inc | Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ES2238969T3 (es) | 1994-05-09 | 2005-09-16 | William J. Binder | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
EP0809509A4 (en) * | 1995-01-13 | 2000-02-02 | Salk Inst For Biological Studi | ALLOSTERIC REGULATION OF NUCLEAR HORMONE RECEPTORS |
US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
FR2763958A1 (fr) * | 1997-05-29 | 1998-12-04 | Transgene Sa | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
US7470431B2 (en) * | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
ES2385130T3 (es) * | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US6428785B1 (en) * | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US20030212021A1 (en) | 2001-01-25 | 2003-11-13 | Frost Gregory I. | Myeloid colony stimulating factor and uses thereof |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
CA2460042C (en) | 2000-09-26 | 2012-05-08 | Sidney Kimmel Cancer Center | Inhibition of antigen presentation with poorly catabolized polymers |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
BR0006556A (pt) * | 2000-12-28 | 2002-09-17 | Apsen Farmaceutica S A | Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose |
US20030113349A1 (en) * | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US20040067235A1 (en) | 2002-07-29 | 2004-04-08 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
WO2004058147A2 (en) | 2002-12-16 | 2004-07-15 | Halozyme, Inc. | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2004110360A2 (en) * | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
GB2417419A (en) * | 2004-07-12 | 2006-03-01 | Ipsen Ltd | Therapeutic use of Botulinum toxin |
EP2248534A1 (en) * | 2005-06-14 | 2010-11-10 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
US20090324647A1 (en) * | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
KR101235135B1 (ko) * | 2005-12-19 | 2013-02-20 | 삼성디스플레이 주식회사 | 금속 배선, 이의 제조 방법, 이를 구비한 표시 기판 및표시 기판의 제조 방법 |
WO2008030638A2 (en) | 2006-05-16 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
EP2583687B1 (en) | 2007-02-15 | 2014-08-27 | Allergan, Inc. | Use of botulinum toxin for treating hyperhydrosis |
-
2008
- 2008-02-14 EP EP13151292.3A patent/EP2583687B1/en not_active Not-in-force
- 2008-02-14 ES ES08743476.7T patent/ES2441961T3/es active Active
- 2008-02-14 WO PCT/US2008/053989 patent/WO2008101098A2/en active Application Filing
- 2008-02-14 EP EP08743476.7A patent/EP2117584B1/en not_active Not-in-force
- 2008-02-14 JP JP2009549723A patent/JP2010519211A/ja active Pending
- 2008-02-14 ES ES13151292.3T patent/ES2520765T3/es active Active
- 2008-02-14 CA CA2678038A patent/CA2678038C/en not_active Expired - Fee Related
- 2008-02-15 US US12/032,013 patent/US8388952B2/en active Active
- 2008-02-15 US US12/032,057 patent/US8383103B2/en active Active
-
2013
- 2013-01-31 US US13/755,282 patent/US8697066B2/en active Active
- 2013-01-31 US US13/755,310 patent/US20130142770A1/en not_active Abandoned
- 2013-10-11 HK HK13111511.2A patent/HK1184055A1/xx not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010519211A5 (ja) | ||
CA2678038A1 (en) | Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis | |
Watanabe et al. | Dynamic change of cells expressing MMP-2 mRNA and MT1-MMP mRNA in the recovery from liver fibrosis in the rat | |
O’Halloran et al. | Adipose-derived stem cells in novel approaches to breast reconstruction: their suitability for tissue engineering and oncological safety | |
CN101939030A (zh) | 藻酸盐低聚物在抗击生物膜中的用途 | |
RU2011143730A (ru) | Децеллюляризации и рецеллюляризация органов и тканей | |
Shaker et al. | Quartz head contact laser fiber: a novel fiber for laser ablation of the prostate using the 980 nm high power diode laser | |
Strup-Perrot et al. | Expression and activation of MMP-2,-3,-9,-14 are induced in rat colon after abdominal X-irradiation | |
AR078291A1 (es) | Composiciones de enzimas pancreaticas y metodos para tratar pancreatitis e insuficiencia pancreatica | |
Zcharia et al. | Heparanase regulates murine hair growth | |
WO2008049058A3 (en) | Cln2 treatment of alzheimer's disease | |
Liu et al. | Effects of Dimethylaminoethanol and Compound Amino Acid on D‐Galactose Induced Skin Aging Model of Rat | |
CN104490727B (zh) | 一种干细胞与玻尿酸的组合物与应用 | |
Guo et al. | Clinical outcomes of endoscopic submucosal dissection for laterally spreading tumors involving the dentate line | |
WO2020219358A3 (en) | Catalytically inactive botulinum neurotoxin-like toxins and uses thereof | |
WO2003033678A3 (en) | Methods of using deacetylase inhibitors to promote cell differentiation and regeneration | |
Gehl et al. | Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy | |
Lionetti et al. | Regenerative medicine approach to repair the failing heart | |
Zhang et al. | Combination treatment with photodynamic therapy and laser therapy in chronic hyperplastic candidiasis: A case report | |
Iwamoto et al. | Autologous transplantation of multilayered fibroblast sheets prevents postoperative pancreatic fistula by regulating fibrosis and angiogenesis | |
CN107088190A (zh) | 富马酸酯在制备治疗肝病药物中的应用 | |
FR2903017B1 (fr) | Compositions cosmetiques contenant un amidon et un diester gras de peg et leurs utilisations | |
CN1980690B (zh) | 含有巴曲酶的恶性肿瘤局部浸润抑制剂 | |
Mancuso et al. | Novel Antimicrobial Approaches to Combat Bacterial Biofilms Associated with UTI | |
CN101294158B (zh) | 一种抑制血管内膜增生的小分子干扰rna |